CN102688247A - Nestorone在制备治疗帕金森氏病的药物用途 - Google Patents
Nestorone在制备治疗帕金森氏病的药物用途 Download PDFInfo
- Publication number
- CN102688247A CN102688247A CN2012101102925A CN201210110292A CN102688247A CN 102688247 A CN102688247 A CN 102688247A CN 2012101102925 A CN2012101102925 A CN 2012101102925A CN 201210110292 A CN201210110292 A CN 201210110292A CN 102688247 A CN102688247 A CN 102688247A
- Authority
- CN
- China
- Prior art keywords
- nestorone
- group
- drugs
- disease
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012101102925A CN102688247A (zh) | 2012-04-15 | 2012-04-15 | Nestorone在制备治疗帕金森氏病的药物用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012101102925A CN102688247A (zh) | 2012-04-15 | 2012-04-15 | Nestorone在制备治疗帕金森氏病的药物用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102688247A true CN102688247A (zh) | 2012-09-26 |
Family
ID=46854092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012101102925A Pending CN102688247A (zh) | 2012-04-15 | 2012-04-15 | Nestorone在制备治疗帕金森氏病的药物用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102688247A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2745847A1 (en) * | 2012-12-21 | 2014-06-25 | The Population Council, Inc. | Progestins for preventing or reducing neurodeneration or ischemic damage |
US9446051B2 (en) | 2009-10-19 | 2016-09-20 | The Population Council, Inc. | Neuroprotection and myelin repair using nestorone® |
US10052335B2 (en) | 2009-10-19 | 2018-08-21 | The Population Council, Inc. | Neuroprotection and myelin repair using Nestorone® |
WO2019075362A1 (en) * | 2017-10-12 | 2019-04-18 | Sage Therapeutics, Inc. | METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011049948A2 (en) * | 2009-10-19 | 2011-04-28 | The Population Council, Inc. | Neuroprotection and myelin repair using nestorone® |
-
2012
- 2012-04-15 CN CN2012101102925A patent/CN102688247A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011049948A2 (en) * | 2009-10-19 | 2011-04-28 | The Population Council, Inc. | Neuroprotection and myelin repair using nestorone® |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9446051B2 (en) | 2009-10-19 | 2016-09-20 | The Population Council, Inc. | Neuroprotection and myelin repair using nestorone® |
US10052335B2 (en) | 2009-10-19 | 2018-08-21 | The Population Council, Inc. | Neuroprotection and myelin repair using Nestorone® |
EP2745847A1 (en) * | 2012-12-21 | 2014-06-25 | The Population Council, Inc. | Progestins for preventing or reducing neurodeneration or ischemic damage |
WO2019075362A1 (en) * | 2017-10-12 | 2019-04-18 | Sage Therapeutics, Inc. | METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Becker et al. | Rapid effects of estrogen or progesterone on the amphetamine-induced increase in striatal dopamine are enhanced by estrogen priming: a microdialysis study | |
Shaham et al. | Exposure to mild stress enhances the reinforcing efficacy of intravenous heroin self-administration in rats | |
Gainetdinov et al. | Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter | |
Passos et al. | Is exercise an alternative treatment for chronic insomnia? | |
Chen et al. | JNK/PI3K/Akt signaling pathway is involved in myocardial ischemia/reperfusion injury in diabetic rats: effects of salvianolic acid A intervention | |
Lapchak et al. | Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery | |
CN102688247A (zh) | Nestorone在制备治疗帕金森氏病的药物用途 | |
Segarra et al. | Estrogen receptors mediate estradiol's effect on sensitization and CPP to cocaine in female rats: role of contextual cues | |
Brown et al. | Reinstatement of cocaine seeking in rats by the pharmacological stressors, corticotropin-releasing factor and yohimbine: role for D1/5 dopamine receptors | |
Ball et al. | Chronic restraint stress during withdrawal increases vulnerability to drug priming-induced cocaine seeking via a dopamine D1-like receptor-mediated mechanism | |
Nishiguchi et al. | Detrusor overactivity induced by intravesical application of adenosine 5′-triphosphate under different delivery conditions in rats | |
Gabriele et al. | Dopamine and glutamate release in the dorsolateral caudate putamen following withdrawal from cocaine self-administration in rats | |
Yuan et al. | Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease | |
Li et al. | Multiple organic cation transporters contribute to the renal transport of sulpiride | |
WO2008040260A1 (es) | Uso del factor de crecimiento epidérmico para la restauración morfofuncional de nervios periféricos en la neuropatía diabética | |
Miguelez et al. | L-DOPA elicits non-vesicular releases of serotonin and dopamine in hemiparkinsonian rats in vivo | |
Li et al. | Modulation of α‐adrenoceptor signalling protects photoreceptors after retinal detachment by inhibiting oxidative stress and inflammation | |
Fraser et al. | the future of bladder control—Intravesical drug delivery, a pinch of pepper, and gene therapy | |
Li et al. | (2R, 6R)-hydroxynorketamine acts through GluA1-induced synaptic plasticity to alleviate PTSD-like effects in rat models | |
Lu et al. | A comparative study of the effect of 17β-estradiol and estriol on peripheral pain behavior in rats | |
Shinno et al. | The relationship of brimonidine concentration in vitreous body to the free concentration in retina/choroid following topical administration in pigmented rabbits | |
Ham et al. | Fraxetin reduces endometriotic lesions through activation of ER stress, induction of mitochondria-mediated apoptosis, and generation of ROS | |
Bertotto et al. | ERK activation in the amygdala and hippocampus induced by fear conditioning in ethanol withdrawn rats: modulation by MK-801 | |
Chan et al. | Metformin in nucleus accumbens core reduces cue‐induced cocaine seeking in male and female rats | |
Cao et al. | Ginkgolide b protects against ischemic stroke via targeting ampk/pink1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: NO. 2 HOSPITAL ATLACHED TO WENZHOU MEDICAL COLLEGE Free format text: FORMER OWNER: WENZHOU MEDICINAL INSTITUTE Effective date: 20120904 Owner name: WENZHOU MEDICINAL INSTITUTE Effective date: 20120904 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 325027 WENZHOU, ZHEJIANG PROVINCE TO: 325000 WENZHOU, ZHEJIANG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120904 Address after: 325000 Wenzhou college, Zhejiang, West Road, No. 109 Applicant after: No. 2 Hospital Atlached to Wenzhou Medical College Applicant after: Wenzhou Medical College Address before: 325027 Wenzhou college, Zhejiang, West Road, No. 82 Applicant before: Wenzhou Medical College |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120926 |